Genetic Stabilization of Transthyretin, Cerebrovascular Disease, and Life Expectancy

Objective—Transthyretin can cause amyloidosis attributable to destabilization of transthyretin tetramers in plasma. We tested the hypothesis that genetic stabilization of transthyretin associates with reduced risk of vascular disease and increased life expectancy. Approach and Results—We included 68 602 participants from 2 prospective studies of the general population. We genotyped for 2 stabilizing genetic variants in the transthyretin gene (TTR), R104H and T119M, and determined the association of genotypes with plasma levels of transthyretin, measures of thyroid function, risk of vascular disease, and life expectancy. During a mean follow-up of 32 years, 10 636 participants developed vascular disease. We identified 321 heterozygotes for T119M (frequency, 0.47%); R104H was not detected. First, mean plasma transthyretin and thyroxine levels were increased by 17% (26 µg/mL) and 20% (19 nmol/L), respectively, in heterozygotes versus noncarriers (P=0.007 and P<0.0001), demonstrating functionality of this variant in the general population. Second, corresponding hazard ratios were 0.70 (95% confidence interval, 0.51–0.97) for all vascular diseases, 0.85 (0.59–1.23) for cardiovascular disease, 0.45 (0.25–0.81) for cerebrovascular disease, 0.47 (0.25–0.88) for ischemic cerebrovascular disease, and 0.31 (0.04–2.22) for hemorrhagic stroke. The cumulative incidence of cerebrovascular disease as a function of age was decreased in heterozygotes versus noncarriers (P=0.005). Third, median age at death from all causes, from vascular and cerebrovascular diseases, and after diagnosis of vascular disease, and median age at diagnosis of vascular disease, was increased by 5 to 10 years in heterozygotes versus noncarriers (P=0.002–0.05). Conclusions—These results are compatible with an association between genetic stabilization of transthyretin and decreased risk of cerebrovascular disease, and with increased life expectancy in the general population.

[1]  M. Yazaki,et al.  [Senile systemic amyloidosis]. , 2014, Brain and nerve = Shinkei kenkyu no shinpo.

[2]  J. Buxbaum,et al.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. , 2013, Biochemistry.

[3]  B. Nordestgaard,et al.  25‐Hydroxyvitamin D and symptomatic ischemic stroke: An Original Study and Meta‐Analysis , 2013, Annals of neurology.

[4]  M. Saraiva,et al.  Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. , 2013, Biochimica et biophysica acta.

[5]  R. Labaudinière,et al.  Tafamidis for transthyretin familial amyloid polyneuropathy , 2012, Neurology.

[6]  Steven M. Johnson,et al.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. , 2012, Journal of molecular biology.

[7]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[8]  S. Ikeda,et al.  Arterial thromboembolism in senile systemic amyloidosis: report of two cases , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  E. Wanker,et al.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report , 2012, Clinical Research in Cardiology.

[10]  M. Saraiva,et al.  Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: “In Vivo” Evidence from FAP Mice Models , 2012, PloS one.

[11]  Xinyi Li,et al.  Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease? , 2011, Molecular Neurodegeneration.

[12]  R. Falk,et al.  Cardiac Amyloidosis: A Treatable Disease, Often Overlooked , 2011, Circulation.

[13]  J. Kelly,et al.  Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. , 2011, Biochemical and biophysical research communications.

[14]  B. Nordestgaard,et al.  Sterol transporter adenosine triphosphate–binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population , 2011, Hepatology.

[15]  A. Akinc,et al.  CSF transthyretin neuroprotection in a mouse model of brain ischemia , 2010, Journal of neurochemistry.

[16]  C. E. Fleming,et al.  Transthyretin: More than meets the eye , 2009, Progress in Neurobiology.

[17]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[18]  Lixia Liu,et al.  Perflint: A Context Sensitive Performance Advisor for C++ Programs , 2009, 2009 International Symposium on Code Generation and Optimization.

[19]  M. Saraiva,et al.  Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors , 2009, PloS one.

[20]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[21]  Pritam Das,et al.  Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity , 2008, Proceedings of the National Academy of Sciences.

[22]  A. Singleton,et al.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study , 2008, Annals of medicine.

[23]  H. Matsubara,et al.  Early cardiac involvement in senile systemic amyloidosis: a case report , 2008, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[24]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[25]  C. E. Fleming,et al.  Transthyretin enhances nerve regeneration , 2007, Journal of neurochemistry.

[26]  Peter Sanders,et al.  MCSTL: the multi-core standard template library , 2007, PPOPP.

[27]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[28]  J. Kelly,et al.  The Biological and Chemical Basis for Tissue-Selective Amyloid Disease , 2005, Cell.

[29]  D. Oreadi,et al.  A clinico-pathologic correlation. , 2005, Journal of the Massachusetts Dental Society.

[30]  William,et al.  The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00) , 2004, Biochemistry (Moscow).

[31]  K. Sletten,et al.  Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[32]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[33]  Janice L Holton,et al.  Sporadic and Familial Cerebral Amyloid Angiopathies , 2002, Brain pathology.

[34]  R. Falk,et al.  Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[35]  J. Kelly,et al.  Trans-Suppression of Misfolding in an Amyloid Disease , 2001, Science.

[36]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[37]  M. Saraiva,et al.  Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. , 2000, Biochemical and biophysical research communications.

[38]  Masahito Yamada,et al.  Cerebral amyloid angiopathy: An overview , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[39]  H. Ideta,et al.  A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. , 1999, Biochemical and biophysical research communications.

[40]  G. Palomaki,et al.  Reference distributions for the negative acute‐phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort , 1999, Journal of clinical laboratory analysis.

[41]  J. Buxbaum,et al.  The systemic amyloidoses. , 1998, The New England journal of medicine.

[42]  M. Saraiva,et al.  Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. , 1997, European journal of biochemistry.

[43]  A. Brouwer,et al.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. , 1997, Endocrine.

[44]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[46]  W. Strittmatter,et al.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. George,et al.  Thyroxine binding by human transthyretin variants: mutations at position 119, but not position 54, increase thyroxine binding affinity. , 1994, The Journal of clinical endocrinology and metabolism.

[48]  J. Palha,et al.  Thyroxine binding in a TTR Met 119 kindred. , 1993, The Journal of clinical endocrinology and metabolism.

[49]  M. Benson,et al.  Biochemical and clinical characterization of prealbuminCHICAGO: an apparently benign variant of serum prealbumin (transthyretin) discovered with high-resolution two-dimensional electrophoresis. , 1991, American journal of medical genetics.

[50]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Schon,et al.  Transthyretin , 1986, Neurology.

[52]  R A Kyle,et al.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.

[53]  M. Devisscher,et al.  [Thyroxine-binding proteins]. , 1968, Annales d'endocrinologie.

[54]  John H. Jopson,et al.  A REPORT OF TWO CASES , 1902 .